Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan
Background The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is used in the Japanese National Immunization Program for older adults and adults with increased risk for pneumococcal disease, however, disease incidence and associated burden remain high. We evaluated the cost-effectiveness of p...
Saved in:
Main Authors: | Shigeki Nakamura, Masashi Mikami, Tomoyuki Hayamizu, Naohiro Yonemoto, Camille Moyon, Mark Gouldson, Catriona Crossan, Jeffrey Vietri, Kazumasa Kamei |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2024-12-01
|
Series: | Expert Review of Vaccines |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/14760584.2024.2350246 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine for routine pediatric vaccination programs in Japan
by: Masayoshi Shinjoh, et al.
Published: (2024-12-01) -
IAPSM’s Position Paper on Pneumococcal Vaccine (PCV) for Adult Immunization in India
by: Chythra R. Rao, et al.
Published: (2024-12-01) -
Indirect protection in adults ≥18 years of age from pediatric pneumococcal vaccination: a review
by: Elmira Flem, et al.
Published: (2024-12-01) -
PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and children
by: Timothy J Chapman, et al.
Published: (2024-12-01) -
Hospital burden of pneumococcal disease in Spain (2016–2022): A retrospective study
by: Ruth Gil-Prieto, et al.
Published: (2025-12-01)